Weight Management Therapy in T2DM

Diabetes is a condition that involves problems regulating blood glucose levels. Weight can play a key role in the disease, as type 2 diabetes (T2DM) can lead to both weight loss and weight gain.

When conventional medications and other types of therapy for T2DM do not
help control blood sugar, insulin therapy is recommended by healthcare  providers. This happens to about 26-27% of people affected with the condition and most people who begin insulin treatment gain weight. T2DM  is characterized by insulin resistance and may lead to weight gain. When the pancreas produces extra insulin due to resistance, the hormone  signals the muscles and liver to store blood sugar. Once these reserves  are full, any extra sugar that the liver has in store is sent off to fat cells, leading to weight gain as well.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used in managing type 2 diabetes, offering benefits such as improved glycemic  control, weight loss, and reduced cardiovascular risks. Semaglutide, a prominent GLP-1 RA used in treating type 2 diabetes and managing weight, has shown significant efficacy in achieving these therapeutic goals. However, it is reported that the individuals with T2DM do not experience such profound weight loss effects from semaglutide than in those with  obesity but not having T2DM, a phenomenon requiring further  research. The semaglutide safety and tolerability profiles are well  established, and it is approved in some countries to reduce cardiovascular risk in certain populations with T2DM.

Thus, semaglutide offers a well-established therapeutic option that  aligns well with guideline recommendations for T2DM management, emphasizing the high importance of weight control and amelioration of  other cardiometabolic risk factors. 

Recognizing the significance of weight management in T2DM, BTL Biotechno Labs Pvt. Ltd., a prominent distributor of life science research  products in India, provides glucagon-like peptide-1 receptor ELISA kits, glucocorticoids, antibodies and other biological reagents to the  scientific community. These offerings aim to support researchers in  their endeavours toward effective weight management in type 2 diabetes.

Glp
For more details, please connect with us at info@biotechnolabs.com

#lifescience #biotechnology #researchanddevelopment #diabetes #type2diabetesmellitus #scientificresearch #glp #glucagonlikepeptide1 #elisa #glucocorticoids #antibodies #proteins #assaykits #biochemicals #smallmolecules #weightloss #btlbiotechnolabspvtltd